Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

Similar articles for PubMed (Select 16109363)

1.

Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action.

Farina C, Weber MS, Meinl E, Wekerle H, Hohlfeld R.

Lancet Neurol. 2005 Sep;4(9):567-75. Review.

PMID:
16109363
2.

Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.

Lalive PH, Neuhaus O, Benkhoucha M, Burger D, Hohlfeld R, Zamvil SS, Weber MS.

CNS Drugs. 2011 May;25(5):401-14. doi: 10.2165/11588120-000000000-00000. Review.

3.

Glatiramer acetate: mechanisms of action in multiple sclerosis.

Schrempf W, Ziemssen T.

Autoimmun Rev. 2007 Aug;6(7):469-75. Epub 2007 Mar 6. Review.

PMID:
17643935
4.

Glatiramer acetate: mechanisms of action in multiple sclerosis.

Ziemssen T, Schrempf W.

Int Rev Neurobiol. 2007;79:537-70. Review.

PMID:
17531858
5.

Risk-benefit assessment of glatiramer acetate in multiple sclerosis.

Ziemssen T, Neuhaus O, Hohlfeld R.

Drug Saf. 2001;24(13):979-90.

PMID:
11735654
6.

Recent insights into the mechanism of action of glatiramer acetate.

Kala M, Miravalle A, Vollmer T.

J Neuroimmunol. 2011 Jun;235(1-2):9-17. doi: 10.1016/j.jneuroim.2011.01.009. Epub 2011 Mar 13. Review.

PMID:
21402415
7.

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.

Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA.

J Clin Invest. 2000 Apr;105(7):967-76.

8.

Mechanism of action of glatiramer acetate in treatment of multiple sclerosis.

Weber MS, Hohlfeld R, Zamvil SS.

Neurotherapeutics. 2007 Oct;4(4):647-53. Review.

PMID:
17920545
9.

The mechanism of action of glatiramer acetate treatment in multiple sclerosis.

Racke MK, Lovett-Racke AE, Karandikar NJ.

Neurology. 2010 Jan 5;74 Suppl 1:S25-30. doi: 10.1212/WNL.0b013e3181c97e39. Review.

PMID:
20038760
10.

First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.

Johnston J, So TY.

Drugs. 2012 Jun 18;72(9):1195-211. doi: 10.2165/11634010-000000000-00000. Review.

PMID:
22642799
11.
12.

The use of glatiramer acetate in the treatment of multiple sclerosis.

Wolinsky JS.

Adv Neurol. 2006;98:273-92. Review.

PMID:
16400839
13.

Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications.

Arnon R, Aharoni R.

Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14593-8. Epub 2004 Sep 15.

14.
15.

Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ.

Aharoni R, Kayhan B, Eilam R, Sela M, Arnon R.

Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14157-62. Epub 2003 Nov 12. Erratum in: Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12288.

16.

Glatiramer acetate (Copaxone) therapy for multiple sclerosis.

Dhib-Jalbut S.

Pharmacol Ther. 2003 May;98(2):245-55. Review.

PMID:
12725872
17.

Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis.

Kim HJ, Ifergan I, Antel JP, Seguin R, Duddy M, Lapierre Y, Jalili F, Bar-Or A.

J Immunol. 2004 Jun 1;172(11):7144-53.

18.

Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells.

Vieira PL, Heystek HC, Wormmeester J, Wierenga EA, Kapsenberg ML.

J Immunol. 2003 May 1;170(9):4483-8.

19.

Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role.

Liblau R.

J Neurol Sci. 2009 Dec;287 Suppl 1:S17-23. doi: 10.1016/S0022-510X(09)71296-1.

PMID:
20106343
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk